US 12,304,912 B2
Fused bicyclic RAF inhibitors and methods for use thereof
Andrew Belfield, Macclesfield (GB); Clifford David Jones, Macclesfield (GB); Jean-François Margathe, Macclesfield (GB); and Chiara Colletto, Macclesfield (GB)
Assigned to Jazz Pharmaceuticals Ireland Limited, Dublin (IE)
Filed by Jazz Pharmaceuticals Ireland Limited, Dublin (IE)
Filed on Nov. 16, 2023, as Appl. No. 18/511,344.
Application 18/511,344 is a division of application No. 17/387,049, filed on Jul. 28, 2021, granted, now 11,858,930.
Claims priority of provisional application 63/057,536, filed on Jul. 28, 2020.
Prior Publication US 2024/0124452 A1, Apr. 18, 2024
Int. Cl. C07D 405/14 (2006.01); A61K 31/4433 (2006.01); A61K 45/06 (2006.01); C07D 471/04 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 45/06 (2013.01); C07D 405/14 (2013.01)] 18 Claims
 
1. A compound of formula (II), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof,

OG Complex Work Unit Chemistry
wherein:
X1 and X2 are each N or CH;
R1 is a substituted C1-8 alkyl, an unsubstituted C5-8 alkyl, a substituted or unsubstituted C1-8 haloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclyl, or a substituted or unsubstituted heteroaryl; and
R4 is —NRFC(O)R5, —NRFC(O)CH2R5, —NRFC(O)CH(CH3)R5, or —NRFR5;
R5 is a substituted or unsubstituted group selected from alkyl, carbocyclyl, aryl, heterocyclyl, or heteroaryl; and
RF is H or C1-3 alkyl.